BNGO - Bionano Genomics: Saphyr System May Be Coming Of Age But Peak Sales Look Years Away

• Bionano stock has skyrocketed in 2021 after narrowly avoiding being delisted in 2020 due to its shares trading <$1.
• The company is commercializing Saphyr, a novel approach to performing cytogenetics and discovery research using Optical Genome Mapping as opposed to short- or long-form sequencing.
• A favorable comparison to Pacific Biosciences' long-form sequencing was one of the catalysts for the strong share price outperformance.
• Saphyr is unlikely to replace gene-sequencing systems in hospitals in research centers because it has fewer use-cases, but it could become a must-have complement.
• Bionano stock trades at $6.20, a 65% discount to its 52-week high of $15.50, and a 93% premium to its 52-week low of $0.40. I think that's where it's likely to stay for the next 6-12 months.

For further details see: